The Compounder Sleeve: Why RGEN, STVN, and WST Beat DHR and TMO from Here

A Portfolio Process Framework for Compounding

One approach to a more ‘institutional’ life sciences investing framework is to own Danaher and Thermo Fisher, let the steady compounding do its work, and feel validated at every JPM week panel. They are outstanding companies and long-term winners but more often than not, they function as late-cycle comfort trades rather than early inflection opportunities. This is not a call to short them—far from it. The question worth asking in early 2026 is whether the smarter risk/reward now sits three levels down the food chain — in the quieter, less-covered, structurally stickier names that are embedded in the same regulated workflows but haven’t been re-rated yet.

The thesis here is simple: Repligen (RGEN), Stevanato (STVN), and West Pharmaceutical Services (WST) represent a more compelling multi-year compounding opportunity than DHR or TMO at this stage of the biotech funding and manufacturing cycle. Not because DHR and TMO are bad businesses — they’re excellent — but because of where we sit in the cycle, where the operating leverage is most underappreciated, and where a re-rating can actually happen without needing the macro to cooperate perfectly.

This post walks through the full argument.